Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of allogeneic CD19 CAR-T cell therapy BRL-303 in relapsed/refractory systemic sclerosis
ChiCTR2600135527Phase 2Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Oct 2026
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of BRL-303 in systemic sclerosis (SSc) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Incidence and severity of adverse events, Incidence and severity of dose-limiting toxicities and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BRL-303
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2600135527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135527.